TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable

Clinical Trial Description

Retrospective database analysis using TriNetX database to describe HES patient characteristics, journey, and disease burden. ;

Study Design

See also
	Status	Clinical Trial	Phase
	No longer available	`NCT04498871` - MAP to Provide Access to Nilotinib, for Patients With HES

See also

Status

Clinical Trial

Phase

No longer available

NCT04498871 - MAP to Provide Access to Nilotinib, for Patients With HES

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06172751
Study type	Observational
Source	AstraZeneca
Contact	AstraZeneca Clinical Study Information Center
Phone	1-877-240-9479
Email	information.center@astrazeneca.com
Status	Recruiting
Phase
Start date	December 15, 2023
Completion date	May 1, 2024

TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms